Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results
oleh: Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Sue E. Bell, Alexander J. Szubert, Nuria Navarro Coy, Gordon Cook, Sylvia Feyler, Peter R.E. Johnson, Claudius Rudin, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Nigel H. Russell, Graham H. Jackson, J. Anthony Child
| Format: | Article |
|---|---|
| Diterbitkan: | Ferrata Storti Foundation 2012-03-01 |
Deskripsi
Background Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation.Design and Methods Oral cyclophosphamide, thalidomide, and dexamethasone was compared with infusional cyclophosphamide, vincristine, doxorubicin, and dexamethasone in patients with newly diagnosed multiple myeloma.Results The post-induction overall response rate (≥ partial response) for the intent-to-treat population was significantly higher with cyclophosphamide-thalidomide-dexamethasone (n=555) versus cyclophosphamide-vincristine-doxorubicin-dexamethasone (n=556); 82.5% versus 71.2%; odds ratio 1.91; 95% confidence interval 1.44–2.55; P